ReviewLangmuir : the ACS journal of surfaces and colloids2025
Bridging the Gap: Unlocking the Potential of Biofabrication for Applications in In Vitro Testing.
Review in Langmuir : the ACS journal of surfaces and colloids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Convergence of Organ-on-a-Chip and Freeform Printing of Sacrificial Poly(2-cyclopropyl-2-oxazoline) Enables the Generation of Perfusable Endothelialized Channels in Hydrogels.Macromolecular rapid communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofabrication holds immense potential for advancing tissue models used in in vitro testing. Despite significant technological advancements, there are currently no commercially viable biofabricated in vitro models, e.g., for drug testing. In contrast, established systems like organ-on-a-chip (OoC) and transwell-based tissue models are widely used, providing reliable solutions for drug testing but with limitations in tissue size, complexity, and customizability. Despite its potential to create complex tissue architectures, biofabrication has yet to become commercially viable. This perspective explores the key technological challenges limiting biofabrication's full potential in commercial in vitro testing and outlines how advancements in matrix compatibility, interface stability, and end-user usability can help overcome these barriers to unlock its transformative impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.